Castle Biosciences (CSTL) Capital Expenditures (2018 - 2026)

Castle Biosciences has disclosed Capital Expenditures across 9 years of filings, most recently posting $8.6 million for Q2 2026.

• In Q2 2026, Capital Expenditures fell 6.62% year-over-year to $8.6 million; the TTM figure through Jun 2026 stood at $43.1 million (up 54.3% YoY), while the FY2025 annual figure was $36.0 million, up 27.17% from the prior year.
• Capital Expenditures came in at $8.6 million for Q2 2026 at Castle Biosciences, down from $12.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $14.8 million in Q3 2025 to a low of $402000.0 in Q1 2022.
• Average Capital Expenditures over 5 years is $5.8 million, with a median of $5.0 million recorded in 2024.
• Year-over-year, Capital Expenditures tumbled 95.67% in 2022 and surged 730.35% in 2023.
• Over 5 years, Capital Expenditures stood at $1.8 million in 2022, then surged by 112.26% to $3.8 million in 2023, then jumped by 99.5% to $7.6 million in 2024, then fell by 5.06% to $7.2 million in 2025, then increased by 20.41% to $8.6 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $8.6 million in Q2 2026, $12.5 million in Q1 2026, and $7.2 million in Q4 2025.